Patents by Inventor Steven M. Chamow
Steven M. Chamow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338282Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: ApplicationFiled: March 22, 2023Publication date: October 26, 2023Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen C. Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Patent number: 11642310Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: GrantFiled: April 7, 2020Date of Patent: May 9, 2023Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Patent number: 11065151Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: GrantFiled: December 18, 2020Date of Patent: July 20, 2021Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20210113374Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: ApplicationFiled: December 18, 2020Publication date: April 22, 2021Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20210025885Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: ApplicationFiled: April 7, 2020Publication date: January 28, 2021Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Patent number: 10874548Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: GrantFiled: May 26, 2017Date of Patent: December 29, 2020Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Patent number: 10656152Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: GrantFiled: November 8, 2017Date of Patent: May 19, 2020Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen C. Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Publication number: 20180292403Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: ApplicationFiled: November 8, 2017Publication date: October 11, 2018Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen C. Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Publication number: 20170258634Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20160287719Abstract: A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.Type: ApplicationFiled: January 12, 2016Publication date: October 6, 2016Inventors: Kathleen Cogan Farinas, Steven M. Chamow
-
Publication number: 20140248296Abstract: A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.Type: ApplicationFiled: August 15, 2013Publication date: September 4, 2014Inventors: Kathleen Cogan Farinas, Steven M. Chamow
-
Patent number: 8808727Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: GrantFiled: March 15, 2013Date of Patent: August 19, 2014Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Giffor, III, K. Angela MacFarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Publication number: 20140031769Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.Type: ApplicationFiled: November 18, 2011Publication date: January 30, 2014Applicant: ForSight Vision4, Inc.Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela MacFarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
-
Publication number: 20130204209Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Inventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Patent number: 8399006Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: GrantFiled: January 29, 2010Date of Patent: March 19, 2013Assignee: Forsight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela Macfarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Publication number: 20110282093Abstract: The invention relates to heterobifunctional polyethylene glycol reagents, methods of producing them and methods of using them.Type: ApplicationFiled: November 12, 2008Publication date: November 17, 2011Applicant: Intradigm CorporationInventors: Daniel E. Levy, Samuel Zalipsky, Steven M. Chamow
-
Publication number: 20100255061Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.Type: ApplicationFiled: January 29, 2010Publication date: October 7, 2010Applicant: ForSight Labs, LLCInventors: Eugene de Juan, JR., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, Hanson S. Gifford, III, K. Angela MacFarlane, Cary J. Reich, Michael Barrett, Randolph E. Campbell, Robert George, Douglas Sutton
-
Publication number: 20040191243Abstract: Stabilized antibody formulations containing histidine are described. In addition, methods of stabilizing liquid formulations of antibodies using histidine are also described. Kits using histidine to stabilize histidine.Type: ApplicationFiled: December 11, 2003Publication date: September 30, 2004Inventors: Bei Chen, Gerardo Zapata, Michael G. Mulkerrin, Steven M. Chamow
-
Patent number: 6582928Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 2, 2000Date of Patent: June 24, 2003Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 6124435Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: December 22, 1998Date of Patent: September 26, 2000Assignee: Genetech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan